Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...

Pfizer (NYSE:PFE) on Tuesday announced that a Phase 3 trial designed to test its FDA-approved antitumor agent Tukysa as a first-line maintenance therapy in breast cancer reached its main goal with a ...

DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal ...

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter ...

A systematic review reveals poor assessment and reporting of health-related quality of life (HRQoL) in early-stage NSCLC ...